These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22875615)

  • 21. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
    Kröger N; Brand R; van Biezen A; Zander A; Dierlamm J; Niederwieser D; Devergie A; Ruutu T; Cornish J; Ljungman P; Gratwohl A; Cordonnier C; Beelen D; Deconinck E; Symeonidis A; de Witte T;
    Haematologica; 2009 Apr; 94(4):542-9. PubMed ID: 19278968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
    J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute myeloid leukemia and myelodysplastic syndromes in older adults.
    Klepin HD; Rao AV; Pardee TS
    J Clin Oncol; 2014 Aug; 32(24):2541-52. PubMed ID: 25071138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.
    Ritchie EK; Klepin HD; Storrick E; Major B; Le-Rademacher J; Wadleigh M; Walker A; Larson RA; Roboz GJ
    Blood Adv; 2022 Jun; 6(12):3812-3820. PubMed ID: 35420672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Choices: A Quality of Life Comparison in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome.
    Tinsley SM; Sutton SK; Thapa R; Lancet J; McMillan SC
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S75-S79. PubMed ID: 28760305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Laribi K; Sobh M; Ghez D; Baugier de Materre A
    Ann Hematol; 2021 Jun; 100(6):1359-1376. PubMed ID: 33796898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
    Talati C; Dhulipala VC; Extermann MT; Ali NA; Kim J; Komrokji R; Sweet K; Kuykendall A; Sehovic M; Reljic T; Djulbegovic B; Lancet JE
    Haematologica; 2020; 105(2):398-406. PubMed ID: 31073071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.
    Molga A; Wall M; Chhetri R; Wee LY; Singhal D; Edwards S; Singhal N; Ross D; To LB; Caughey G; Shakib S; Germing U; To T; Hiwase D
    J Geriatr Oncol; 2020 Jan; 11(1):114-120. PubMed ID: 31023599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-reported outcomes in acute myeloid leukemia: Where are we now?
    Buckley SA; Kirtane K; Walter RB; Lee SJ; Lyman GH
    Blood Rev; 2018 Jan; 32(1):81-87. PubMed ID: 28888621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.
    Klepin HD
    Clin Geriatr Med; 2016 Feb; 32(1):155-73. PubMed ID: 26614866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
    Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
    Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.
    Ball B; Komrokji RS; Adès L; Sekeres MA; DeZern AE; Pleyer L; Vey N; Almeida A; Germing U; Cluzeau T; Platzbecker U; Gore SD; Fenaux P; Prebet T
    Blood Adv; 2018 Aug; 2(16):2063-2071. PubMed ID: 30120104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
    Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
    JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.